HEALTH.2013.2.4.1-1
HEALTH.2013.2.4.1-1
3 projects · €15,150,423 total EU contribution (project-level) · 55 participating organizations · 11 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€15,150,423
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (16)
- UK (9)
- France (8)
- Italy (5)
- AT (4)
- BE (4)
- Spain (3)
- IE (2)
- Netherlands (2)
- CZ (1)
- SE (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- ASSISTANCE PUBLIQUE HOPITAUX DE PARIS2 projects · FR
- CLB2 projects · FR
- Leiden University Medical Center1 projects · NL
- G-AGO1 projects · DE
- ARCAGY ASSOCIATION1 projects · FR
- BHSCT1 projects · UK
- CENTRE REGIONAL FRANCOIS BACLESSE1 projects · FR
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN1 projects · DE
- ERASMUS MC1 projects · NL
- EORTC1 projects · BE
- INT1 projects · IT
- FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE1 projects · ES
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
A drug strategy targeting heat shock protein 90 to combat metastatic, p53 mutant ovarian cancer. GANNET53 · 602602 | FP7 | €5,994,072 | €7,752,629 | Details |
EURO EWING Consortium – International Clinical Trials to Improve Survival from Ewing Sarcoma EEC · 602856 | FP7 | €5,697,831 | €7,428,275 | Details |
A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients. MERCURIC · 602901 | FP7 | €3,458,520 | €4,552,219 | Details |